Rationale and Design of CASPER: Compliance and Quality of Life Study Comparing Once-Daily Carvedilol CR and Twice-Daily Carvedilol IR in Patients with Heart Failure

American Journal of Cardiology

Volumn 98, Issue 7 SUPPL., 2006, Pages 60-66

  Hauptman, Paul J ^a   Pressler, Susan J ^b   Sackner Bernstein, Jonathan ^c   Ordronneau, Paul ^d   Udelson, James E ^e  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF NURSING   (United States)

^c Clinilabs Inc   (United States)

^d GLAXOSMITHKLINE   (United States)

^e TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; DRUG SAFETY; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; PATIENT COMPLIANCE; PROPANOLAMINES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 33749118012     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.08.004     Document Type: Article

References (29)

1. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
2. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 (1987) 1429-1435
3. Garg R., Yusuf S., and Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 273 (1995) 1450-1456
4. Cohn J.N., and Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
5. Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., Michelson E.L., Olofsson B., Ostergren J., Yusuf S., and Pocock S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
6. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H., and US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 (1996) 1349-1355
7. Packer M., Fowler M.B., Roecker E.B., Coats A.J., Katus H.A., Krum H., Mohacsi P., Rouleau J.L., Tendera M., Staiger C., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation 106 (2002) 2194-2199
8. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
9. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 78 (1996) 902-907
10. Masoudi F.A., Baillie C.A., Wang Y., Bradford W.D., Steiner J.F., Havranek E.P., Foody J.M., and Krumholz H.M. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998-2001. Arch Intern Med 165 (2005) 2069-2076
11. Borzecki A.M., Oliveria S.A., and Berlowitz D.R. Barriers to hypertension control. Am Heart J 149 (2005) 785-794
12. Osterberg L., and Blaschke T. Adherence to medication. N Engl J Med 353 (2005) 487-497
13. Spertus J.A., Dewhurst T., Dougherty C.M., and Nichol P. Testing the effectiveness of converting patients to long-acting antianginal medications: the Quality of Life in Angina Research Trial (QUART). Am Heart J 141 (2001) 550-558
14. Claxton A.J., Cramer J., and Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23 (2001) 1296-1310
15. Vinson J.M., Rich M.W., Sperry J.C., Shah A.S., and McNamara T. Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc 38 (1990) 1290-1295
16. Bennett S.J., Huster G.A., Baker S.L., Milgrom L.B., Kirchgassner A., Birt J., and Pressler M.L. Characterization of the precipitants of hospitalization for heart failure decompensation. Am J Crit Care 7 (1998) 168-174
17. Granger B.B., Swedberg K., Ekman I., Granger C.B., Olofsson B., McMurray J.J., Yusuf S., Michelson E.L., and Pfeffer M.A. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 366 (2005) 2005-2011
18. Wetzels G.E., Nelemans P., Schouten J.S., and Prins M.H. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens 22 (2004) 1849-1855
19. Tu W., Morris A.B., Li J., Wu J., Young J., Brater D.C., and Murray M.D. Association between adherence measurements of metoprolol and health care utilization in older patients with heart failure. Clin Pharmacol Ther 77 (2005) 189-201
20. Testa M.A., Anderson R.B., Nackley J.F., Hollenberg N.K., and Quality-of-Life Hypertension Study Group. Quality of life and antihypertensive therapy in men: a comparison of captopril with enalapril. N Engl J Med 328 (1993) 907-913
21. Green C.P., Porter C.B., Bresnahan D.R., and Spertus J.A. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 35 (2000) 1245-1255
22. Atkinson M.J., Sinha A., Hass S.L., Colman S.S., Kumar R.N., Brod M., and Rowland C.R. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2 (2004) 12
23. Oswald A.J. Happiness and economic performance. Economics Journal 107 (1997) 1815-1831
24. Kroenke K., Spitzer R.L., and Williams J.B. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 64 (2002) 258-266
25. Waeber B. What has been learned from electronic monitoring of compliance with antihypertensive medications?. J Hypertens 22 (2004) 1857-1858
26. Andrejak M., Genes N., Vaur L., Poncelet P., Clerson P., and Carre A. Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: comparison of once daily versus twice daily regimen. Am J Hypertens 13 (2000) 184-190
27. Straka R.J., Fish J.T., Benson S.R., and Suh J.T. Patient self-reporting of compliance does not correspond with electronic monitoring: an evaluation using isosorbide dinitrate as a model drug. Pharmacotherapy 17 (1997) 126-132
28. Kardas P. Comparison of once daily versus twice daily oral nitrates in stable angina pectoris. Am J Cardiol 94 (2004) 213-216
29. Dunbar-Jacob J., Bohachick P., Mortimer M.K., Sereika S.M., and Foley S.M. Medication adherence in persons with cardiovascular disease. J Cardiovasc Nurs 18 (2003) 209-218